{"meshTagsMajor":["Precision Medicine"],"keywords":["Breast cancer","Estrogen receptor","HER2 positive breast cancer","Personalized medicine","Triple negative breast cancer"],"meshTags":["Precision Medicine","Female","Receptors, Progesterone","Breast Neoplasms","Receptor, ErbB-2","Mutation","Humans","Receptors, Estrogen"],"meshMinor":["Female","Receptors, Progesterone","Breast Neoplasms","Receptor, ErbB-2","Mutation","Humans","Receptors, Estrogen"],"organisms":["9606"],"publicationTypes":["Journal Article","Lectures"],"abstract":"Breast cancer remains the most common cancer diagnosed in women in the United States and is second only to lung cancer as a cause of cancer mortality. Breast cancer has become the prototypical solid tumor where targets have been identified within the tumor allowing for a personalized approach of systemic therapy. ","title":"Personalized medicine for breast cancer: it is a new day!","pubmedId":"24581758"}